Lower prices for 15 drugs, including Ozempic and Wegovy, are expected to be announced by the end of the month. The price ...

The deal, with Eli Lilly and Novo Nordisk, is expected to lower the price of obesity drugs to between $149 and $350 per month ...

Even by dramatically lowering the prices of some of its medications, the drug giant is still outpacing its rivals and nearing ...

Trump administration drug deals link U.S. prices to global lows, aiming to cut costs via Pfizer, AstraZeneca, and TrumpRx in 2026.

Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some ...

Eli Lilly’s stock is experiencing a remarkable surge, nearing an all-time high as strategic price cuts on key drugs like ...

A sweeping deal to slash the price of popular obesity drugs is poised to reshape American healthcare, signaling a rare convergence of trade policy and public health strategy. Under a proposed ...

President Donald Trump says Americans could soon pay far less for GLP-1 medications used for diabetes, obesity, and heart ...

Experts analyze how Trump's drug pricing policies, including Most Favored Nation (MFN) and tariffs, reshape pharma markets and impact patient costs and access.

The Trump administration announced deals on Thursday with pharmaceutical giants Novo Nordisk and Eli Lilly that would lower ...

With pricing pressures climbing, Pfizer, Eli Lilly and other major drugmakers are looking to sell their products directly to ...

Competition is working, even as the FTC meddles in a takeover fight in a way that helped Pfizer.